- Home
- CNF vs BEAT Comparison
CNF vs BEAT Comparison
Compare CNF & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- BEAT
- Stock Information
- Founded
- CNF 1999
- BEAT 2015
- Country
- CNF China
- BEAT United States
- Employees
- CNF N/A
- BEAT N/A
- Industry
- CNF Finance: Consumer Services
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- CNF Finance
- BEAT Technology
- Exchange
- CNF Nasdaq
- BEAT Nasdaq
- Market Cap
- CNF 59.0M
- BEAT 65.1M
- IPO Year
- CNF 2018
- BEAT 2021
- Fundamental
- Price
- CNF $1.12
- BEAT $2.08
- Analyst Decision
- CNF
- BEAT Buy
- Analyst Count
- CNF 0
- BEAT 1
- Target Price
- CNF N/A
- BEAT $8.00
- AVG Volume (30 Days)
- CNF 22.5K
- BEAT 132.5K
- Earning Date
- CNF 03-27-2025
- BEAT 03-19-2025
- Dividend Yield
- CNF N/A
- BEAT N/A
- EPS Growth
- CNF N/A
- BEAT N/A
- EPS
- CNF 0.24
- BEAT N/A
- Revenue
- CNF $109,788,152.00
- BEAT N/A
- Revenue This Year
- CNF N/A
- BEAT N/A
- Revenue Next Year
- CNF $13.09
- BEAT N/A
- P/E Ratio
- CNF $4.67
- BEAT N/A
- Revenue Growth
- CNF 12.99
- BEAT N/A
- 52 Week Low
- CNF $0.81
- BEAT $1.35
- 52 Week High
- CNF $2.84
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- CNF 47.25
- BEAT 39.34
- Support Level
- CNF $1.07
- BEAT $2.05
- Resistance Level
- CNF $1.23
- BEAT $2.37
- Average True Range (ATR)
- CNF 0.09
- BEAT 0.18
- MACD
- CNF -0.02
- BEAT -0.02
- Stochastic Oscillator
- CNF 20.87
- BEAT 21.24
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.